• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Study reveals large disparities in survival for patients with HPV-associated cancers

Bioengineer by Bioengineer
November 6, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new study found large disparities by sex, race, and age in survival for patients diagnosed with different cancers caused by the human papillomavirus (HPV). Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that improvements in HPV vaccination and access to cancer screening and treatment are needed.

HPV causes most cases of cervical cancer, but it can also cause cancers in other parts of the body, including the oropharynx (the base of the tongue, the tonsils, and the back of the throat), vagina, vulva, penis, and anus. More than 38,000 HPV-associated cancers are diagnosed annually in the United States.

Investigators at the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion looked to see how survival rates vary for each of these cancers by certain demographic characteristics, such as race and age. The team examined data from 27 population-based cancer registries covering approximately 59 percent of the US population. The researchers focused on invasive cancer diagnosed from 2001-2011 and followed these cases through 2011.

The five-year relative survival was 64 percent for cervical carcinomas, 53 percent for vaginal, 66 percent for vulvar, 47 percent for penile, 66 percent for anal, 56 percent for rectal, and 51 percent for oropharyngeal squamous cell carcinomas. Five-year relative survival was consistently higher among white individuals than black individuals for all HPV-associated cancers and all age groups, and the largest differences were for oropharyngeal squamous cell carcinomas among those younger than 60 years and for penile squamous cell carcinomas among those aged 40-49 years compared with other age groups. Also, older people with HPV-associated cancers tended to die sooner after diagnosis than younger people, and men with an HPV-associated cancer of the anus were likely to die sooner than women with the same cancer.

"This new study shows that race, sex, and age can make a difference in surviving HPV-associated cancers said co-author Mona Saraiya, MD, MPH. "There are things that people can do to avoid getting an HPV-related cancer, or to help improve their chances of survival such as getting the HPV vaccine when recommended at the age of 11 or 12 years old (or as early as age 9 and as late as age 26); getting screened for cervical cancer at the recommended ages; and for those who have been diagnosed with an HPV-associated cancer, working with their healthcare provider to create a personalized plan for care. Health care providers can take steps to assure that they are offering the recommended screening and treatment, regardless of a patient's race, age or sex."

###

Additional Information

Full Citations: "Five-Year Relative Survival for Human Papillomavirus-Associated Cancer Sites." Hilda Razzaghi, Mona Saraiya, Trevor Thompson, Jane Henley, Laura Viens, and Reda Wilson. CANCER; Published Online: November 6, 2017 (DOI: 10.1002/cncr.30947).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.30947 Editorial: "Survival of Human Papillomavirus-Associated Cancers: Filling In the Gaps." Nosayaba Osazuwa-Peters, Sean T. Massa, Matthew C. Simpson, Eric Adjei Boakye, Mark A. Varvares. CANCER; Published Online: November 6, 2017 (DOI: 10.1002/cncr.30945).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.30945

Author Contact: [email protected] or +1 (404) 639-3286.

About the Journal

CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.

Follow us on Twitter @JournalCancer and Facebook https://www.facebook.com/ACSJournals

About Wiley

Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Media Contact

Dawn Peters
[email protected]

http://newsroom.wiley.com/

http://dx.doi.org/10.1002/cncr.30947

Share15Tweet8Share2ShareShareShare2

Related Posts

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

February 7, 2026

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

February 7, 2026

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

February 7, 2026

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.